Drug Dosage
The author and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

Copyright 1983 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
Printed in Germany by Mhlberger KG, D-890 Augsburg
ISBN 3-8055-3653-4

Contents

Preface ..................................................................................................................... VII

Perevodchikova, N. (Moscow): Opening Remarks .............................................. 1
Brade, W. P.; Herdrich, K. (Frankfurt): Tegafur - a Review of Pharmacology and Toxicology ................................................................. 2
Van Putten, L. ; Lelieveld, P. (Rijswijk): Effects of Divided versus Single Doses of
Contents VI


Hattori, T.; Niimoto, M.; Oride, M. (Hirosima); Inokuchi, K. (Fukuoka); Taguchi, T. (Osaka): Postoperative Chemotherapy with Futraful and Mitomycin C and Chemo-Immunotherapy in Gastric Cancer ....................................................... 103

Anssfield, F. J.; Kallas, G. J.; Singson, J. P.; Uy, B. P. (Milwaukee/Wisconsin): Phase I-II Studies of Intravenous Tegafur (Ftorafur) ......................................................... 118

Perevodchikova, N. (Moscow): A Comparative Evaluation of Ftorafur and 5-Fluorouracil within Combination Chemotherapy (HexaCAF vs. HexaCAFt) of Ovarian Cancer ................................................................................................................. 127
As very often, contradictory clinical results have been the stimulus for the 1st International Workshop on Tegafur, held in Vienna in February 1982. Most of the presently available experimental and clinical data were presented there and critically analyzed in discussion. Whereas no doubt exists in the single agent antitumor activity of tegafur in gastrointestinal, breast and ovarian carcinoma, tegafur-containing combination chemotherapy, especially in gastrointestinal cancer, revealed conflicting results. Since from single-drug studies with tegafur strong dependence of efficacy and safety on dose and schedule is apparent, it is understandable that the higher efficacy and better tolerance of combination chemotherapy as compared to single agent treatment has not always been reached in the past. Thus, more efficacious schedules have to be developed, very likely not using the low dose fractionation over 5 days and cumulative doses lower than 20 g.

The editors wish to thank all the authors and participants of the workshop for their contributions. The critical reading of the manuscripts by Dr. Herdrich enabled us to delete errors. We are also indebted to the publisher, the Karger-Verlag, Germering/Munich.

October 1982 The Editors